Dr.M.shafiee Department of internal medicine Shiraz university of medical sciences.

Slides:



Advertisements
Similar presentations
Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group Auckland City Hospital 2 nd Sept 2011.
Advertisements

Congestive Heart Failure
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 9 th Lecture.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
In the Name of God In the Name of God Overview of Hypertension Mahboob Lessan Pezeshki MD Tehran University of Medical Sciences Aban 1392.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
Drugs for Hypertension
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
Drugs Acting on the Renin-Angiotensin-Aldosterone System
 Edmond 75 years presented with ‘shocking” blood pressure recordings of 184/102 in the morning. His afternoon and night readings were in the ‘acceptable.
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Nursing and heart failure
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
Radka Adlová Arterial hypertension and preventive cardiology.
Heart Failure. Background to Congestive Heart Failure Normal cardiac output needed to adequately perfuse peripheral organs – Provide O 2, nutrients, etc.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
HTN Cases Pharmacotherapy - 1. Case 1 TJ is a 45-year-old woman with a history of type 2 diabetes mellitus treated with glyburide 5 mg/ day. She.
– Dr. J. Satish Kumar, MD, Department of Basic & Medical Sciences, AUST General Medicine CVS Name:________________________________________ Congestive Heart.
Michelle Gardner RN NUR-224. OBJECTIVES  Define normal blood pressure and categories of abnormal pressure  Identify risk factors for hypertension 
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Hypertension In Hemodialysis Patients Dr. Shahrokh Ezzatzadegan Department of Internal Medicine Shiraz University of Medical Sciences.
HTN & CKD 1. HTN has been reported to occur in 85-95% of patients with CKD (stages 3–5). The relationship between HTN & CKD is cyclic in nature. Uncontrolled.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Resistant Hypertension Topic Discussion Brian Skinner, PharmD PGY-1 Pharmacy Resident St. Vincent Indianapolis Hospital.
Clinical Management of primary hypertension
JNC VIII Hypertension.
CREATED BY Prof. Azza El-Medany
Drugs Used to Treat Heart Failure
Hypertension JNC VIII Guidelines.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Nursing Care of Patients with Hypertension
Blood Pressure Regulation 2
Drugs for Hypertension
Health and Human Services National Heart, Lung, and Blood Institute
Intensive Hemodialysis: Applied Clinical Practice
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Udayan Bhatt, MD MPH OSU Nephrology
Hypertension Pharmcology.
HTN Cases Pharmacotherapy - 1.
THE SILENT KILLER HYPERTENSION.
Antihypertensive Drugs
Achieving the Clinical Potential of RAAS Blockade
Primary Efficacy End Point.
Acute and Chronic Renal Failure
Hypertension in Dialysis Patients
Hypertension: A Risk Factor For Stroke
UNIT 2: ANTIHYPERTENSIVE DRUGS
Progress and Promise in RAAS Blockade
Hypertension Guidelines
Hypertension in Dialysis Patients
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation  Anil K. Bidani, M.D., Karen A. Griffin,
Step Care Therapy for Hypertension in Diabetic Patients
UNIT 2: ANTIHYPERTENSIVE DRUGS
Drugs Acting on the Renin-Angiotensin-Aldosterone System
Essential Hypertension
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Effect of β-adrenergic Blockers on the Arterial Blood Pressure
Primary Hypertension Max C. Reif, M.D.
Anti hypertensive Drugs
Drugs Acting on the Heart
The following slides highlight a report by Dr
Internal Medicine Workshop Series Laos September /October 2009
Drugs Affecting Blood Pressure
Hypertensive Crisis Halmat M. Jaafar (MSc. Clinical pharmacy)
Presentation transcript:

Dr.M.shafiee Department of internal medicine Shiraz university of medical sciences

 mean home BP>135/85  mean ABPM>130/80  Mean interdialytic BP at mead week >140/90

 Dialysis Unit: During, Before, or After  Home BP  ABPM

 Predialysis SBP overestimated mean SBP by an average of 10 mm Hg  Postdialysis SBP underestimated mean SBP by an average of 7 mm Hg  BP readings over a period of 1 to 2 weeks rather than isolated readings should be used

 Sodium and volume overload.  Sympathetic nervous system activity  Inappropriate renin secretion.  Alteration in endothelin and nitric oxide.  Erythropoietin therapy.  Hyperparathyroidism.  Others: Uremic toxins, Nocturnal hypoxemia and sleep disturbances  Essential Hypertension before ESRD

 Hypervolemia is the major factor  Positive Sodium balance  Increases intake and decreased excretion  Achieving DW will control 60% of cases of HTN

Management

 Step 1: Lifestyle modifications and control of volume status with lifestyle modifications.  Step 2: Control of volume status with dialysis.  Step 3: Administration of antihypertensive drugs

 Restriction of Na and water and fluid  Restriction of salt to maximum 5gr per day  Exercise

 Control of volume status  Limit interdialytic weight gain  a 2.5 kg is associated with a significant increase in BP  Achieve dry weight  Frequent dialysis & Longer dialysis time

 Criteria to determining DW:  No marked fall in BP during dialysis.  No hypertension (predialysis BP at the beginning of the week <140/90 mm Hg).  No peripheral edema.  No pulmonary congestion on chest X-ray.  Cardiothoracic ratio ≤50% (≤53% in females).

 Na restriction and dry weight can control BP in % of patients  The absence of edema dose not exclude the hypervolemia

 Antihypertensive drugs are indicated in patients in whom hypertension persist, despite seemingly adequate volume control  All classes of antihypertensive drugs can be used in dialysis patients, with the sole exception of diuretics  The selection of antihypertensive agents is frequently dictated by the presence of comorbid conditions

 ARBs and ACE are the preferable first line of antihypertensive drugs  They are well tolerated and are particularly effective in patients with a history of heart failure due to systolic dysfunction and may induce a more rapid regression of LVH  They may aggravate anemia by reducing the action of erythropoietin

 They are indicated in patients who have had a recent MI or suffer from angina pectoris  Potential side effects include CNS depression Bradycardia, altered lipid profiles,hyperkalemia altered response to hypoglycemia and bronchospasm

 They are effective and well tolerated in dialysis patients  In this group Amlodipin can decrease mortality

 Methyl doppa and clonidine are in this group  But due to infavorable side effects use of them are limitted

 Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive agents of different classes

 The use of non steroidal anti-inflammatory drugs  Renovascular hypertension  Increasing cysts in polysystic kidney disease  Compliance

 If a treatable cause cannot be found,minoxidil in combination with beta blocker may be effective  Spironolactone in Hemodialysis Patients mg post dialysis  Risk of hyperkalemia  Improve EF and Improve BP control  Large studies are done

 Renal sympathetic nerve ablation  Bilateral nephrectomy May be considered in the rare, noncompliant individual with life-threatening hypertension unable to be controlled with any dialysis modality

 5-15%  Mechanism  Endothelial dysfunction  Activation of renin angiotensin system  Sodium level  Activation of systematic nervous system  Extracellular volume overload

 The most important treatment is adequate sodium and water removal and reducing sympathetic hyperactivity.  Changing to non-dialyzable antihypertensive medications  Altering the dialysis prescription

 ACEI or αblocker at the time of hypertension or befor hemodialysis  Carvedilol, which blocks endothelin-1 release, appears to be effective in this setting

Thank you